Back to Search
Start Over
Genetic resistance for antiplatelet drugs: aspirin, clopidogrel, ticagrelor, prasugrel
Genetic resistance for antiplatelet drugs: aspirin, clopidogrel, ticagrelor, prasugrel
- Publication Year :
- 2016
- Publisher :
- Institutional Repository of Lithuanian University of Health Sciences, 2016.
-
Abstract
- The main problem of this work – the expected antiplatelet effect is not always achieved and it depends on the patients` genotype. In order to achieve the required therapeutic effect, the genes, affecting the therapeutic effect of these drugs should be performed The aim of this study was to estimate the factors, impacting the resistance to antiplatelet therapy in patients following stent implantation (SI) or in patients after coronary artery bypass grafting (CABG) by using platelet aggregation, clinical and genetic data. Main tasks: to estimate the influence of clinical factors on the platelet aggregation (PA) during induction and long-term treatment in patients following SI, also, to find the impact of genotype and concomitant use of drugs on PA values in these patients; to find the distribution of genotypes in the patients who followed antiplatelet therapy after CABG or SI. Methods: Real-Time PCR was used to determine the CYP2C19*2 and CYP4F2 G1347A genotypes. Fisher exact test was used to compare categorical variables. Hardy Weinberg method was used to show the concordance of analyzed patients genotypes to a normal population genotype distribution. A p value
- Subjects :
- CYP2C19*2
CYP4F2 G1347A
clopidogrel
ticagrelor
Subjects
Details
- Language :
- Lithuanian
- Database :
- OpenAIRE
- Accession number :
- edsair.od......2888..7fe7409b7a0a1523ce0ec112ab2772f8